Bisphosphonates in the Treatment of Metabolic Bone Diseases

References

• Fleisch H. Biphosphonates: pharmacology and use in the treatment of tumour‐induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919–35
   PubMed Web of Science ®Google Scholar
• Lin J, Duggan D E, Chen I W, Ellsworth R L. Physiological disposition of alendronate, a potent anti‐osteolytic bisphos‐phonate, in laboratory animals. Drug Metab Dispos 1991; 19: 926–32
   PubMed Web of Science ®Google Scholar
• Sletsema W K, Ebetino F H, Salvagno A M, Bevan J A. Antiresorptive dose‐response relationships across three generations of biphosphonates. Drugs Exp Clin Res 1989; 15: 389–96
   PubMedGoogle Scholar
• Francis M D. The inhibition of calcium hydroxyapatite crystal growth. Calcif Tissue Res 1969; 3: 151–62
   PubMedGoogle Scholar
• Schenk R, Mere W A, Muhlbauer R, Russell R GG, Fleisch H. Effect of ethane‐1‐hydroxy‐1,1‐diphosphonate (EHDP) and dichloromethylene diphosphonate (CI2 MDP) on the calcification and resorption of cartilage and bone in the tribial epiphysis and metaphysis of rats. Calcif Tissue Res 1973; 11: 196–214
   PubMedGoogle Scholar
• Sato M, Grasser W, Endo N, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095–105
   PubMed Web of Science ®Google Scholar
• Zimolo Z, Tanaka H, Rodan G A. Alendronate (ALN) increases the membrane permeability of multinucleated osteoclast‐like cells to NH4+, H+ and C++. Bone Miner 1992; 17: S146
   Google Scholar
• Felix R, Bettex J D, Fleisch H. Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif Tissue Intl 1981; 33: 549–52
   PubMedGoogle Scholar
• Sahnl M, Guenther H L, Martin T J, Fleisch H. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Bone Miner Res 1992; 7(Suppl 1)S128
   Google Scholar
• Thompson D D, Seedor J G, Weinreb M, Rosini S, Rodan G A. Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats. J Bone Miner Res 1990; 5: 279–86
   PubMed Web of Science ®Google Scholar
• Thompson D D, Seedor J G, Quartuccio H, et al. The bisophosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res 1992; 7: 951–60
   PubMed Web of Science ®Google Scholar
• Gertz B J, Kline W F, Matuszewski B K, Sacco J F, Lasserter K C, Porras A G. Oral bioavailability and dose proportionality of alendronate (aminohydroxybutylidene bisphosphonate) in postmenopausal women. J Bone Miner fles 1991; 6(Suppl 1)S281
   Google Scholar
• Lin J H, Chen L ‐W, Duggan D E. Effects of dose, sex and age on the disposition of alendronate, a potent anti‐osteolytic bisphosphonate, in rats. Drug Metab Dispos 1992; 20: 608–13
   PubMed Web of Science ®Google Scholar
• Fitton A, McTavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289–318
   PubMed Web of Science ®Google Scholar
• Mundy G R. Hypercalcemia of malignancy revisited. J Clin Invest 1988; 82: 1–6
   PubMed Web of Science ®Google Scholar
• Mosekilde L, Eriksen E F, Charles P. Hypercalcemia of malignancy: pathophysiology, diagnosis and treatment. Crit Rev Oncol Hematol 1991; 11: 1–27
   PubMed Web of Science ®Google Scholar
• Ralston S H, Danks J, Hayman J, Fraser W D, Stewart C S, Martin T J. Parathyroid hormone‐related protein in malignancy: immunohistochemical and biochemical studies in normocalcaemic and hypercalcaemic patients with cancer. J Clin Pathol 1991; 44: 472–6
   PubMedGoogle Scholar
• Adami S, Bolzicco G P, Rizzo A, et al. The use of dichloro‐methylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner 1987; 2: 395–404
   PubMedGoogle Scholar
• Blckerstaff D R, O'Doherty D P, McCloskey E V, Hamdy N AT, Mian M, Kanis J A. Effects of amino‐butylidene diphosphonate in hypercalcemia due to malignancy. Bone 1991; 12: 17–20
   PubMed Web of Science ®Google Scholar
• Zysset E, Ammann P, Jenzer A, et al. Comparison of a rapid (2‐h) versus a slow (24‐h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Sone Miner 1992; 18: 237–49
   Google Scholar
• Rizzoli R, Buchs B, Bonjour J ‐P. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate. Int J Cancer 1992; 51: 1–7
   PubMedGoogle Scholar
• Daragon A, Peyron R, Serrurier D, Deshayes P. Treatment of hypercalcaemia of malignancy with intravenous aminohydroxypropylidene bisphosphonate. Curr Therapeut Res 1991; 50: 10–21
   Web of Science ®Google Scholar
• Gucalp R, Ritch P, Wiernik P H, et al. Comparative study of pamidronate and disodium and etidronate disodium in the treatment of cancer‐related hypercalcemia. J Clin Oncol 1992; 10: 134–42
   PubMed Web of Science ®Google Scholar
• Fatemi S, Singer F R, Rude R K. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 1992; 50: 107–9
   PubMed Web of Science ®Google Scholar
• Dumon J C, Magritte A, Body J J. Efficacy and safety of the bisphosphonate Tiiudronate for the treatment of tumor‐associated hypercalcemia. Bone Miner 1991; 15: 257–66
   PubMedGoogle Scholar
• Kanis J A, McCloskey E V, Paterson A HG. Use of diphos‐phonates in hypercalcaemia due to malignancy. Lancet 1990; 335: 170–1
   PubMedGoogle Scholar
• Schenk R, Eggli P, Felix H, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tiss Int 1986; 38: 342–9
   PubMed Web of Science ®Google Scholar
• Percival R C, Urwin G H, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987; 13: 41–9
   PubMedGoogle Scholar
• Attardo‐Parrinello G, Merlini G, Pavesi F, Crema F, Fiorentini M L, Ascari E. Effects of a new aminodiphos‐phonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis; comparison with dichloromethylene diphosphonate. Arch Intern Med 1987; 147: 1629–33
   PubMed Web of Science ®Google Scholar
• Martoni A, Guaraldi M, Camera P, et al. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. Oncology 1991; 48: 97–101
   PubMed Web of Science ®Google Scholar
• Canfield R E, Rosner W, Skinner J, et al. Disphosphonate therapy in Paget's disease of bone. J Clin Endocrinol Metab 1977; 11: 96–106
   Google Scholar
• McCloskey E V, Yates A JP, Gray R ES, Hamdy N AT, Galloway J, Kanis J A. Disphosphonates and phosphate homeostasis in man. Clin Sci 1988; 74: 607–12
   Web of Science ®Google Scholar
• Gray R ES, Yates A JP, Preston C J, Smith R, Russell R GG, Kanis J A. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Quart J Med, New Series 1987; 64(245)755–67
   PubMedGoogle Scholar
• Meunier P J, Chapuy M C, Alexandre C, et al. Effects of disodium dichloromethylene diphosphonate in Paget's disease of bone. Lancet 1979; ii: 489
   Google Scholar
• Adami S, Salvagno G, Guarrera G, et al. Treatment of Paget's disease of bone with intravenous 4‐amino‐1‐hydroxybutylidene‐1,1‐bisphosphonate. Calcif Tissue Int 1986; 39: 226–9
   PubMed Web of Science ®Google Scholar
• Pedrazonni M, Palummeri E, Ciotti G, et al. Short‐term effects on bone and mineral metabolism of 4‐amino‐1‐hydroxybutylidene‐1,1‐diphosphonate 9ABDP) in Paget's disease of bone. Bone Miner 1989; 7: 301–7
   PubMedGoogle Scholar
• O'Doherty D P, Gertz B J, Tindale W, Sciberras D G, Survill T T, Kanis J A. Effects of five daily 1 h infusions of alendronate in Paget's disease of bone. J Bone Miner Res 1992; 7: 81–7
   PubMed Web of Science ®Google Scholar
• O'Doherty D P, Bickerstaff D R, McCloskey E V, et al. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res 1990; 5: 483–91
   PubMed Web of Science ®Google Scholar
• Wronski T J, Dann L M, Scott K S, Cintron M. Long‐term effects of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 1989; 45: 360–66
   PubMed Web of Science ®Google Scholar
• Seedor J G, Quartuccio H A, Thompson D D. The bisphosphonate alendronate (MK‐217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 1991; 6: 339–46
   PubMed Web of Science ®Google Scholar
• Wronski T J, Yen C ‐F, Scott K S. Estrogen and diphosphonate treatment provide long‐term protection against osteopenia in ovariectomized rats. J Bone Miner Res 1991; 6: 387–94
   PubMed Web of Science ®Google Scholar
• Toolan B C, Shea M, Myers E R, et al. Effects of 4‐amino‐1‐hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 1992; 7: 1399–406
   PubMed Web of Science ®Google Scholar
• Balena R, Markatos A, Lafage M ‐H, Masarachia P, Gentile M, Rodan G A. The long term effects of alendronate on bone remodeling in the spine of ovariectomized baboons. J Bone Miner Res 1992; 7(Suppl 1)S113
   Google Scholar
• Toolan B C, Shea M, Myers E R, et al. The effect of long term alendronate treatment on vertebral strength in ovariectomized baboons and rats. J Bone Miner Res 1991; 6(Suppl 1)S248
   Google Scholar
• Balena R, Lafage M ‐H, Markatos A, Seedor J G, Rodan G A. The effect of two years alendronate treatment on cortical bone remodeling. J Bone Miner Res 1992; 7(Suppl 1)S328
   Google Scholar
• Passeri M, Baroni M C, Pedrazzoni M, et al. Intermittent treatment with intravenous 4‐amino‐1‐hydroxybutylidene‐1,1‐bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991; 15: 237–48
   PubMedGoogle Scholar
• Reginster J Y, Deroisy R, Denis D, et al. Prevention of postmenopausal bone loss by tiiudronate. Lancet Dec 23/30, 1989; 1469–71
   PubMed Web of Science ®Google Scholar
• Storm T, Thamsborg G, Steiniche T, Genant H K, Sorensen O HN. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265–71
   PubMed Web of Science ®Google Scholar
• Watts N B, Harris S T, Genant H K, Wasnich R, Miller P D. Intermittent cyclical etidronate treatment in postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–9
   PubMed Web of Science ®Google Scholar
• Valkema R F, Vismans J FE, Papapoulos S E, Pauwels E KJ, Bijvoet O LM. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989; 5: 183–92
   PubMedGoogle Scholar
• Papapoulos S E, Landman J O, Bijvoet O LM, et al. The use of bisphosphonates in the treatment of osteoporosis. Bone 1992; 13: 41–9, (Suppl)
   PubMed Web of Science ®Google Scholar
• Frost H M. A new direction for osteoporosis research: a review and proposal. Bone 1991; 12: 429–37
   PubMed Web of Science ®Google Scholar
• Rodan G A. Perspectives: mechanical loading, estrogen deficiency, and the coupling of bone formation to bone resorption. J Bone Miner Res 1991; 6: 527–30
   PubMed Web of Science ®Google Scholar
• Lafage M H, Balena R, Battle M, et al. Comparison of alendronate and sodium fluoride in minipigs: a 1‐year study. Calcif Tissue Int 1993; 52: S96, (Suppl.)
   Google Scholar
• Black D M, Cummlngs S R, Genant H K, Nevitt M C, Palermo L, Browner W. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992; 7: 633–8
   PubMed Web of Science ®Google Scholar
• Libanati C R, Schulz E E, Shook J E, Bock M, Baylink D J. Hip mineral density in females with a recent hip fracture. J Clin Endocrinol Metab 1992; 74: 351–6
   PubMed Web of Science ®Google Scholar
• Gardsell P, Johnell O, Nilsson B E. The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years. Calcif Tissue Int 1991; 49: 90–4
   PubMed Web of Science ®Google Scholar
• Cummlngs S R, Black D, Nevitt M C, et al. Appendicular bone density and age predict hip fracture in women. JAMA 1990; 263: 665–8
   PubMed Web of Science ®Google Scholar
• Wasnich R O, Ross P D, Heilbrun L K, Vogel J M. Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol 1985; 153: 745–51
   PubMed Web of Science ®Google Scholar